Drugs / V941
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03948763 | Jun 2019 → Aug 2022 | colorectal neoplasm, non-small cell lung carcinoma, pancreatic neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V941 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03948763 ↗ |
| Route | Intramuscular | “V941(mRNA-5671/V941) 1 mg administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles” NCT03948763 ↗ |